Association between anti-TNF and NSAID therapy and choroidal and macular thickness in ankylosing spondylitis: an OCT-based study

Basit Öğe Kaydı
dc.contributor.authorGok, Zarife Ekici
dc.contributor.authorAltuner, Mehmet Sakir
dc.contributor.authorMutlu, Kayhan
dc.date.accessioned2026-06-19T06:38:17Z
dc.date.available2026-06-19T06:38:17Z
dc.date.issued2026
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractThis prospective, cross-sectional study aimed to evaluate the association between non-steroidal anti-inflammatory drugs (NSAIDs) and anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy and retinal and choroidal thickness in patients with ankylosing spondylitis (AS) without uveitis, and to compare these findings with healthy controls. A total of 65 AS patients and 30 age- and sex-matched healthy controls were included. Macular thickness, retinal nerve fiber layer (RNFL) thickness, and subfoveal choroidal thickness were measured using spectral-domain optical coherence tomography (SD-OCT). Patients receiving NSAIDs and/or sulfasalazine (Group 1, n = 30) were compared with patients receiving anti-TNF-alpha therapy (Group 2, n = 35) and healthy controls (Group 3, n = 30). Mean subfoveal choroidal thickness was significantly greater in Group 1 compared with controls (p = 0.026). Nasal inner (p = 0.008) and nasal outer (p = 0.003) macular subfield thicknesses were significantly lower in both AS groups compared with controls, while RNFL thickness did not differ significantly among groups (p = 0.069). Analysis of covariance (ANCOVA) showed that age and disease duration had no significant effect on these outcomes. These findings indicate that choroidal and macular thickness measurements are associated with AS even in the absence of clinically evident uveitis, and that anti-TNF-alpha therapy is associated with lower choroidal thickness compared with NSAID treatment. OCT-based choroidal assessment may provide additional information on ocular structural changes associated with AS; however, its role in treatment monitoring requires confirmation in longitudinal studies.
dc.identifier.doi10.1186/s12886-026-04619-w
dc.identifier.issn1471-2415
dc.identifier.issue1
dc.identifier.orcid0000-0002-7558-0615
dc.identifier.pmid41526890
dc.identifier.scopus2-s2.0-105029571161
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12886-026-04619-w
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5489
dc.identifier.volume26
dc.identifier.wosWOS:001686048900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260612
dc.subjectAnkylosing Spondylitis
dc.subjectOptical Coherence Tomography
dc.subjectChoroid
dc.subjectMacular Thickness
dc.subjectAnti-Tnf Therapy
dc.titleAssociation between anti-TNF and NSAID therapy and choroidal and macular thickness in ankylosing spondylitis: an OCT-based study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu